Search research articles
Contact Us
Filters
Showing results (441-450 of 453) with videos related to
Page
of 46
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2021
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>
Y Di Filippo, S Dalle, L Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort
M Kandel, C Allayous, S Dalle, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Allergy
|
March 10, 2011
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper
I Baiardini, F Braido, C Bindslev-Jensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
L Kandolf-Sekulovic, K Peris, A Stratigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
L Kandolf Sekulovic, K Peris, A Hauschild, et al.
Page
of 46
Search research articles
Search
Showing results (441-450 of 453) with videos related to
Sort By:
Page
of 46
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2021
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>
Y Di Filippo, S Dalle, L Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort
M Kandel, C Allayous, S Dalle, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Allergy
|
March 10, 2011
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper
I Baiardini, F Braido, C Bindslev-Jensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
L Kandolf-Sekulovic, K Peris, A Stratigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
L Kandolf Sekulovic, K Peris, A Hauschild, et al.
Page
of 46